

SEP 27 2004  
OPIE JC106 OFFICE  
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**For: G PROTEIN-COUPLED RECEPTOR  
AGONISTS OR ANTAGONISTS**

) **Group Art Unit:** 1614  
)  
) **Examiner:** To be assigned  
)  
) **Customer No.:** 36183  
)  
)  
)  
)  
)  
)

## TRANSMITTAL LETTER

Sir:

Enclosed are the following documents:

- Supplemental Information Disclosure Statement;
- Form PTO/SB/08A; and
- Return Postcard;


No fee is believed due with this submission; however, the Commissioner is authorized to charge any fee required to our Deposit Account No. **50-2613**.

**CERTIFICATE OF MAILING**  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 23, 2001  
Date of Deposit  
SAN/98153.1

Timothy Lusher  
Name of Person Mailing Paper

  
Signature of Person Mailing Paper


Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated:

Sept 23, 2007

By:

  
Jane K. Babin  
Reg. No. 47,224

**PAUL, HASTINGS, JANOFSKY & WALKER LLP**

P.O. Box 919092

San Diego, CA 92191-9092

Phone: (858) 720-2500

Fax: (858) 720-2555



Patent  
39038.00002.CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Sylvain, Chemtob et al.

Serial No.: 10/678,413

Filed: October 02, 2003

**For: G PROTEIN-COUPLED RECEPTOR  
AGONISTS OR ANTAGONISTS**

)  
) **Group Art Unit: 1614**

)  
) **Examiner: To be assigned**

)  
) **Customer No.: 36183**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the Applicant's duty under 37 CFR § 1.56, the following information is brought to the attention of the Examiner.

---

**CERTIFICATE OF MAILING**  
(37 CFR §1.8 a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

---

September 23, 2004  
Date of Delivery

---

Timothy Lister  
Name of Person Delivering Paper

---

Timothy Dasher  
Signature of Person Delivering Paper

**REFERENCES**

- ☐ The references are listed on the attached Form PTO/SB/08a and copies are enclosed for the convenience of the Examiner.
- ☒ Copies of the references listed on the attached Form PTO/SB/08a have already been submitted in corresponding Patent Application No. 09/783,334 & 09/154,627 and therefore, copies of the same are not enclosed.
- ☒ Pursuant to the Patent Office waiver of 37 C.F.R. 1.98(a)(2)(i) (<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/idswouscopies.htm>), copies of U.S. Patents and U.S. Patent application publications are not enclosed herewith.

The items identified in this Supplemental Information Disclosure Statement may or may not be “material” pursuant to 37 CFR § 1.56 and the submission thereof by Applicant shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.

**DISCLOSURE**

☒ The attached Supplemental IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c)

☐ The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(c) and 1.98. This IDS is being filed after an action on the merits but before a Final Action under § 1.113 or a Notice of Allowance under § 1.311. In the event that this IDS is not received before a Final Action under § 1.113 or a Notice of Allowance under § 1.311, the Applicant respectfully requests the filing of these papers to be considered a petition requesting consideration of this IDS pursuant to 37 CFR § 1.97(d).

☐ The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(d) and 1.98. This IDS is being filed after receipt of a final action but before receipt of a Notice of Allowance Under § 1.311.

**Statement Under 37 C.F.R. 1.97(e)(1) and 1.97(e)(2)**

☐ I certify that pursuant to 37 CFR 1.97(e)(1), each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

☐ I certify that pursuant to 37 CFR 1.97(e)(2), no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the best of my knowledge, no item of information contained in this Information Disclosure Statement was known to any individual more than three months prior to the filing of this Information Disclosure Statement.

**PAYMENT METHOD**

- ☐ Enclosed is a check to cover the fee pursuant to 37 CFR § 1.17(p).
- ☒ The Examiner is hereby authorized to charge any fee due with this filing to our Deposit Account No. **50-2613**.
- ☐ The Examiner is hereby authorized to charge any additional fee(s) required by this paper to our Deposit Account No. **50-2613**.

Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER

Dated:

Sept 23, 2004

By:

  
Jane K. Babin

Reg. No. 47,224

P.O. Box 919092  
San Diego, California 92191-9092  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/678,413
				<b>Filing Date</b>	October 02, 2003
				<b>First Named Inventor</b>	Sylvain, Chemtob et al.
				<b>Group Art Unit</b>	1614
				<b>Examiner Name</b>	To be assigned
<b>Sheet</b>	1	of	3	<b>Attorney Docket Number</b>	39038.00002.CIP

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>a</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	CI	20030017988		Peri, Krishna G et al.	01-23-2003	
	CJ	3,691,016		Ravindra	09-12-1972	
	CK	3,969,287		Jaworek; Dieter et al.	07-13-1976	
	DL	4,195,128		Hildebrand; Dietrich et al.	03-25-1980	
	DM	4,229,537		Hodgins; Leonard T et al.	10-21-1980	
	DN	4,247,642		Hirohara; Hideo et al.	01-27-1981	
	DO	4,330,440		Ayers; John S. et al.	05-18-1982	
	DP	4,522,752		Sisto; Alessandro et al.	06-11-1985	
	DQ	5,508,384		Murphy; Randall B. et al.	04-16-1996	
	DR	5,605,814		Abramovitz; Mark et al.	02-25-1997	
	DS	5,688,938		Brown et al.	11-18-1997	
	DT	5,759,789		Abramovitz; Mark et al.	06-02-1998	
	DU	5,955,575		Peri; Krishna G. et al.	09-21-1999	
	DV	6,300,312		Chemtob; Sylvain et al.	10-9-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
	DW	WO	93/09104		Hagen et al.	05-13-1993		
	DX	WO	95/00551		Abramovitz et al.	01-05-1995		
	DY	WO	96/23225		Sundelin et al.	08-01-1996		

<b>Examiner Signature</b>	SAN/98156.1	<b>Date Considered</b>	
---------------------------	-------------	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/678,413
		<b>Filing Date</b>	October 02, 2003
		<b>First Named Inventor</b>	Sylvain, Chemtob et al.
		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	To be assigned
		<b>Attorney Docket Number</b>	39038.00002.CIP
<b>Sheet</b>	<b>2</b>	<b>of</b>	<b>3</b>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	DZ	ABRAMOVITZ, et al. "Cloning and Expression of a cDNA for the Human Prostanoid FP Receptor" Journal of Biol. Chem. Vol. 269, No. 4 pp. 2632-2636, January 28, 1994.	
	EA	BERRIDGE, et al. "Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides" Biochem. J. Vol. 212, pp. 473-482 (1983)	
	EB	COLEMAN, et al "VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and their Subtypes", Pharmacological Reviews, Vol. 46, No. 2, pp. 205-229 (1999).	
	EC	GRIFFIN et al. "AL-8810: A Novel Prostaglandin F <sub>2a</sub> Analog with Selective Antagonist Effects at the Prostaglandin F <sub>2a</sub> (FP) Receptor", The Journal of Pharmacology and Experimental Therapeutics Vol. 290 No. 3, pp. 1278-1284, 1999.	
	ED	GOETZL et al. "Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases", The FASEB Journal, Vol. 9, pp. 1051-1058, August 1995.	
	EE	KITANAKA, et al. "Phloretin as an Antagonist of Prostaglandin F <sub>2a</sub> Receptor in Cultured Rat Astrocytes", Journal of Neurochemistry, Vol. 60. No. 2, pp. 704-708, 1993	
	EF	LI et al. "Key Role for cyclooxygenase-2 in PGE <sub>2</sub> and PGF <sub>2a</sub> receptor regulation and cerebral blood flow of the newborn", The American Physiological Society, pp. R1283-R1290 (1997).	
	EG	LI et al. "Inhibition of Prostaglandin Synthesis in Newborn Pigs Increases Cerebral Microvessel Prostaglandin F <sub>2a</sub> and Prostaglandin E <sub>2</sub> Receptors, Their Second Messengers and Vasoconstrictor Response to Adult Levels", The Journal of Pharmacology and Experimental Therapeutics, Vol. 278, No. 1, pp. 370-377 (1996)	
	EH	POTVIN, et al. "Refractoriness of the gravid rat uterus to tocolytic and biochemical effects of atrial natriuretic peptide" Br. J. Pharmacol., Vol. 100, pp. 341-347 (1990)	
	EI	STRADER, et al. "Structure and Function of G Protein-Coupled Receptors" Annu. Rev. Biochem. 63:101-32 (1994)	
	EJ	SUGIMOTO et al. "Failure of Parturition in Mice Lacking the Prostaglandin F Receptor", Science Vol. 277, pp. 681-683, August 1997.	
<b>Examiner Signature</b>	SAN/98156.1		<b>Date Considered</b>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/678,413
				<b>Filing Date</b>	October 02, 2003
				<b>First Named Inventor</b>	Sylvain, Chemtob et al.
				<b>Group Art Unit</b>	1614
				<b>Examiner Name</b>	To be assigned
<b>Sheet</b>	3	<b>of</b>	3	<b>Attorney Docket Number</b>	39038.00002.CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	EK	VARMA et al. "Endothelium- and Beta-2 Andrenoreceptor-Independent Relaxation of Rat Aorta by Tyramine and Certain other Phenylethylamines" The Journal of Pharmacology and Experimental Therapeutics, Vol. 265, No. 3, pp. 1096-1104 (1993),	

<b>Examiner Signature</b>	SAN/98156.1	<b>Date Considered</b>	
---------------------------	-------------	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.